Corcept Therapeutics (CORT) Long-Term Deferred Tax (2017 - 2026)

Corcept Therapeutics (CORT) has 10 years of Long-Term Deferred Tax data on file, last reported at $181.6 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 25.7% year-over-year to $181.6 million; the trailing twelve-month figure through Mar 2026 stood at $181.6 million (up 25.7% YoY), and the FY2025 full-year result was $168.2 million, up 28.48% from the prior year.
• Long-Term Deferred Tax improved to $181.6 million in Q1 2026, from $168.2 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $181.6 million in Q1 2026 to a low of $37.7 million in Q1 2022.
• A 5-year average of $106.2 million and a median of $97.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Peak annual rise in Long-Term Deferred Tax reached 123.88% in 2022, while the deepest fall reached 1.86% in 2022.
• Tracing CORT's Long-Term Deferred Tax over 5 years: stood at $61.5 million in 2022, then jumped by 47.41% to $90.6 million in 2023, then surged by 44.49% to $130.9 million in 2024, then grew by 28.48% to $168.2 million in 2025, then grew by 7.95% to $181.6 million in 2026.
• Business Quant data shows CORT's Long-Term Deferred Tax at $181.6 million in Q1 2026, $168.2 million in Q4 2025, and $153.0 million in Q3 2025.